Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATRX loss |
| Therapy | Topotecan |
| Indication/Tumor Type | glioblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATRX loss | glioblastoma | sensitive | Topotecan | Preclinical | Actionable | In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505). | 26936505 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26936505) | ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. | Full reference... |